Funding for this research was provided by:
Received: 5 March 2022
Revised: 6 May 2022
Accepted: 12 May 2022
First Online: 25 May 2022
: HW has received honoraria from Novartis. SS has received honoraria from Incyte, Novartis, Pfizer, Bristol Myers Squibb, and Roche and research support from Incyte, Novartis, and Bristol Myers Squibb. J-MC has received research support and honoraria from Incyte, and honoraria from Novartis and Cepheid. TL has received honoraria from Incyte, Novartis, Pfizer, Angelini, Bristol Myers Squibb, and research support from Incyte, Novartis, and Pfizer. PV has received honoraria from Astra-Zeneca, Eli Lilly, Gilead; GlaxoSmithKline, Novartis, Pfizer, Roche, Teva, and research support from Novartis and Pfizer. SM is employed by the MLL Munich Leukemia Laboratory GmbH, Munich. CD and MM are employed by the Institute for Hematology and Oncology (IHO GmbH), Mannheim. KMP has received honoraria from Angelini and Incyte. AH received research support from Novartis, BMS, Pfizer, and Incyte. NC has received research support and honoraria from Novartis, and honoraria from Incyte and Astellas.